Novo Nordisk CEO: 2035 Pipeline Sales Target Is 'Risk Adjusted'

* Shares in Novo Nordisk fall 6% after the Wegovy maker posted its strategic ambitions for 2030 ahead of its Capital Markets Day * Novo says it targets to deliver pipeline sales of more than 150 billion Danish crowns ($23 billion) by 2035 and to increase its obesity customers 10 times * But Nordnet analyst Per Hansen says the stock falls as there is no significant short-term news * Shares are at the lowest level since April, falling 19% year-to-date ($1 = 6.5138 Danish crowns) (Reporting by Boleslaw Lasocki) ((boleslaw.lasocki@thomsonreuters.com )